Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair

The median survival for patients with locally advanced pancreatic cancer treated with gemcitabine and radiation is approximately one year. To develop improved treatment, we have combined a Chk1/2 targeted agent, AZD7762, currently in Phase I clinical trials, with gemcitabine and ionizing radiation i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Morgan, Meredith A., Parsels, Leslie A., Zha, Lili, Parsels, Joshua D., Davis, Mary A., Hassan, Maria C., Arumugarajah, Sankari, Hylander-Gans, Linda, Morosini, Deborah, Simeone, Diane M., Canman, Christine E., Normolle, Daniel P., Zabludoff, Sonya D., Maybaum, Jonathan, Lawrence, Theodore S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2889008/
https://ncbi.nlm.nih.gov/pubmed/20501833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3573
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados